| Mixed (n=123) | Cholesterogenic (n=55) | Glycolytic (n=76) | Quiescent (n=90) | Total (n=344) | P value |
---|---|---|---|---|---|---|
Age | ||||||
 Mean (SD) | 57.5 (15.4) | 54.6 (17.1) | 61.1 (14.4) | 57.5 (16.5) | 57.8 (15.8) | 0.159a |
 Median [MIN,MAX] | 57 [15,90] | 56 [19,82] | 63 [18,90] | 57 [18,90] | 58 [15,90] |  |
Gender | ||||||
 Female | 44 (35.8%) | 18 (32.7%) | 29 (38.2%) | 38 (42.2%) | 129 (37.5%) | 0.668b |
 Male | 79 (64.2%) | 37 (67.3%) | 47 (61.8%) | 52 (57.8%) | 215 (62.5%) |  |
Race | ||||||
 Asian | 5 (4.1%) |  | 2 (2.6%) | 2 (2.2%) | 9 (2.6%) |  |
 White | 118 (95.9%) | 55 (100.0%) | 74 (97.4%) | 88 (97.8%) | 335 (97.4%) |  |
Pathological T | ||||||
 T0 | 11 (8.9%) | 4 (7.3%) | 3 (3.9%) | 5 (5.6%) | 23 (6.7%) | 0.4b |
 T1 | 14 (11.4%) | 8 (14.5%) | 6 (7.9%) | 8 (8.9%) | 36 (10.5%) |  |
 T2 | 29 (23.6%) | 11 (20.0%) | 17 (22.4%) | 15 (16.7%) | 72 (20.9%) |  |
 T3 | 27 (22.0%) | 12 (21.8%) | 25 (32.9%) | 18 (20.0%) | 82 (23.8%) |  |
 T4 | 42 (34.1%) | 20 (36.4%) | 24 (31.6%) | 44 (48.9%) | 130 (37.8%) |  |
 Tis |  |  | 1 (1.3%) |  | 1 (0.3%) |  |
Pathological N | ||||||
 N0 | 77 (62.6%) | 35 (63.6%) | 39 (51.3%) | 46 (51.1%) | 197 (57.3%) | 0.693b |
 N1 | 22 (17.9%) | 10 (18.2%) | 14 (18.4%) | 18 (20.0%) | 64 (18.6%) |  |
 N2 | 13 (10.6%) | 5 (9.1%) | 11 (14.5%) | 12 (13.3%) | 41 (11.9%) |  |
 N3 | 11 (8.9%) | 5 (9.1%) | 12 (15.8%) | 14 (15.6%) | 42 (12.2%) |  |
Pathological M | Â | Â | Â | Â | Â | |
 M0 | 122 (99.2%) | 51 (92.7%) | 72 (94.7%) | 87 (96.7%) | 332 (96.5%) | 0.077b |
 M1 | 1 (0.8%) | 4 (7.3%) | 4 (5.3%) | 3 (3.3%) | 12 (3.5%) |  |
Pathological stage | Â | Â | Â | Â | Â | |
 Stage I | 34 (27.6%) | 10 (18.2%) | 13 (17.1%) | 13 (14.4%) | 70 (20.3%) | 0.143b |
 Stage II | 39 (31.7%) | 22 (40.0%) | 24 (31.6%) | 31 (34.4%) | 116 (33.7%) |  |
 Stage III | 49 (39.8%) | 18 (32.7%) | 35 (46.1%) | 41 (45.6%) | 143 (41.6%) |  |
 Stage IV | 1 (0.8%) | 4 (7.3%) | 4 (5.3%) | 3 (3.3%) | 12 (3.5%) |  |
 I/II NOS |  | 1 (1.8%) |  | 2 (2.2%) | 3 (0.9%) |  |
Overall survival | Â | Â | Â | Â | Â | |
 Survival | 60 (48.8%) | 26 (47.3%) | 32 (42.1%) | 58 (64.4%) | 176 (51.2%) | 0.024c (*) |
 Death | 63 (51.2%) | 29 (52.7%) | 44 (57.9%) | 32 (35.6%) | 168 (48.8%) |  |
Progress-free interval | Â | Â | Â | Â | Â | |
 Free survival | 37 (30.1%) | 11 (20.0%) | 16 (21.1%) | 43 (47.8%) | 107 (31.1%) | <0.001c (*) |
 Death or progression | 86 (69.9%) | 44 (80.0%) | 60 (78.9%) | 47 (52.2%) | 237 (68.9%) |  |